托珠单抗治疗COVID-19导致继发感染风险的Meta分析

A Meta-analysis of the Risk of Secondary Infection of Tocilizumab in the Treatment of COVID-19

目的通过Meta分析评估托珠单抗(tocilizumab,TCZ)治疗新型冠状病毒感染(corona virus disease2019,COVID-19)导致的继发感染风险,为托珠单抗在COVID-19患者中应用的安全性提供循证依据。方法在The Cochrane Library、PubMed、Web of Science、中国知网、中国生物医学文献数据库以及万方数据库中检索了2019年12月19日至2022年12月30日期间使用托珠单抗治疗COVID-19患者的相关研究,筛选并提取文献中发生继发感染的数据,利用RevMan 5.4.1进行Meta分析。结果共筛选了1691篇参考文献,纳入18项研究,涉及3933名患者。托珠单抗+标准治疗组继发感染发生率为19.14%(331/1729),标准治疗组继发感染发生率为12.11%(267/2204)。Meta分析结果显示,托珠单抗+标准治疗组继发感染发生率高于标准治疗组[RR=1.35,95%CI(1.05,1.74),P=0.02]。亚组分析显示,使用不同剂量的托珠单抗发生继发感染的风险不同。托珠单抗给药剂量为400~800 mg/d的亚组继发感染发生率明显高于标准治疗组,差异具有统计学意义[RR=1.48,95%CI(1.19,1.84),P=0.0004];≤400 mg/d继发感染发生率也显著高于标准治疗组,差异具有统计学意义[RR=1.87,95%CI(1.28,2.72),P=0.001];托珠单抗给药剂量为6~8 mg/kg亚组与标准治疗组比较差异无统计学意义。结论与标准治疗相比,托珠单抗可能增加COVID-19患者发生继发感染的风险,临床给药前应仔细评估使用托珠单抗治疗的利益和风险。但是,目前仍需要更多大样本、高质量的研究来进一步评估。

Objective Meta-analysis was conducted to assess the risk of secondary infection caused by tocilizumab(TCZ)in the treatment of Corona Virus Disease 2019(COVID-19),in order to provide an evidence-based basis for the safety of tocilizumab in patients with COVID-19.Methods Cochrane Library,PubMed,Web of Science,CNKI,SinoMed and Wanfang databases were searched in computer to collect randomized controlled trial and cohort study of treating COVID-19 with tocilizumab from December 19,2019 to December 30,2022.A meta-analysis of the results of each study was performed using RevMan 5.4.1 software.Results A total of 1691 references were screened and eighteen studies involving 3933 patients were included.The incidence of secondary infection in the tocilizumab with the standard treatment group and standard treatment group was 19.14%(331/1729)and 12.11%(267/2204),respectively.Meta-analysis showed that the tocilizumab+standard treatment group had a higher incidence of secondary infection than the standard treatment group[RR=1.35,95%CI(1.05,1.74),P=0.02].The results of the subgroup analysis showed that the risk of secondary infection with different doses of tocilizumab was different.The incidence of secondary infection was significantly higher in the subgroup with doses of 400~800 mg/d tocilizumab than in the standard care group[RR=1.48,95%CI(1.19,1.84),P=0.0004].The incidence of secondary infection in subgroups with doses of≤400 mg/d tocilizumab was also significantly higher than that in the standard treatment group[RR=1.87,95%CI(1.28,2.72),P=0.001].However,there was no statistical significance between the subgroup 6~8 mg/kg tocilizumab and the standard treatment group.Conclusions Tocilizumab may increase the risk of secondary infection in patients with COVID-19 compared with standard treatment,and the benefits and risks of tocilizumab should be carefully evaluated before clinical administration.Moreover,large and high-quality studies are needed for further evaluation.